Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rociletinib in EGFR-mutant NSCLC (TIGER-2)
NCT02147990Phase 2Terminated
- Sponsor
- Clovis Oncology
- Start
- Jun 2014
- Primary completion
- Jul 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 2 trial of rociletinib in non-small cell lung cancer (NSCLC), sponsored by Clovis Oncology. Started Jun 2014; status: terminated.
02
Drugs
rociletinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02147990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02147990.